All news

Imatinib and persistence of leukaemia stem cells

Added: Thursday 3 November 2011

A recent study shows that while imatinib mesylate (IM) treatment reduces the burden of leukaemia stem cells in chronic myelogenous leukaemia (CML) patients, there is selective retention of these cells. The results clearly showed that BCR-ABL+ stem cells persist in CML patients despite prolonged treatment with IM.